{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T09:40:01Z","timestamp":1738230001870,"version":"3.34.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,5,17]],"date-time":"2008-05-17T00:00:00Z","timestamp":1210982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s00482-008-0657-5","type":"journal-article","created":{"date-parts":[[2008,5,15]],"date-time":"2008-05-15T17:35:38Z","timestamp":1210872938000},"page":"562-570","source":"Crossref","is-referenced-by-count":3,"title":["Differenzialtherapeutische Aspekte in der Schmerztherapie mit retardierten, oralen, stark wirksamen Opioiden","Differential therapeutic aspects of analgesia with oral sustained-release strong opioids"],"prefix":"10.1007","volume":"22","author":[{"given":"K.","family":"G\u00fcttler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sabatowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,17]]},"reference":[{"key":"657_CR1","unstructured":"Bundesministerium f\u00fcr Bildung und Forschung (2008) Chronischer Schmerz, Ergebnisse der Forschung verbessern die Versorgung der Patienten. BMBF Publik. http:\/\/www.gesundheitsforschung-bmbf.de"},{"key":"657_CR2","unstructured":"World Health Organization (2003) Cancer pain relief, 2nd edn. WHO, Geneva, 1996"},{"key":"657_CR3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1054\/bjoc.2001.1680","volume":"84","author":"Hanks","year":"2001","unstructured":"Hanks GW, Conno F, Cherny N et al. (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587\u2013593","journal-title":"Br J Cancer"},{"key":"657_CR4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/archinte.167.6.540","volume":"167","author":"Kripalani","year":"2007","unstructured":"Kripalani S, Yao X, Haynes RB (2007) Interventions to enhance medication adherence in chonic medical conditions. Arch Intern Med 167: 540\u2013550","journal-title":"Arch Intern Med"},{"key":"657_CR5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0885-3924(89)90005-5","volume":"4","author":"Ventafridda","year":"1989","unstructured":"Ventafridda V, Saita L, Barletta L et al. (1989) Clinical observations on controlled release morphine in cancer pain. J Pain Symptom Manage 4: 124\u2013129","journal-title":"J Pain Symptom Manage"},{"key":"657_CR6","first-page":"521","volume":"16","author":"Ferrell","year":"1989","unstructured":"Ferrell B, Wisdom C, Wenzl C, Brown J (1989) Effects of controlled-released morphine on quality of life for cancer pain. Oncol Nurs Forum 16: 521\u2013526","journal-title":"Oncol Nurs Forum"},{"key":"657_CR7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00000421-199206000-00018","volume":"15","author":"Walsh","year":"1992","unstructured":"Walsh TD, MacDonald N, Bruera E et al. (1992) A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer. Am J Clin Oncol 15: 268\u2013272","journal-title":"Am J Clin Oncol"},{"key":"657_CR8","doi-asserted-by":"crossref","unstructured":"Gupta S, Sathyan G (2007) Providing constant analgesia with OROS\u00ae hydromorphone. J Pain Symptom Manage 33 [suppl 2]: S19\u2013S24","DOI":"10.1016\/j.jpainsymman.2006.09.009"},{"key":"657_CR9","first-page":"CD003868","volume":"4","author":"Wiffen","year":"2003","unstructured":"Wiffen PJ, Edwards JE, Barden J, McQuay HJ (2003) Oral morphine for cancer pain. Cochrane Database Syst Rev 4: CD003868","journal-title":"Cochrane Database Syst Rev"},{"key":"657_CR10","first-page":"CD003447","volume":"1","author":"Quigley","year":"2002","unstructured":"Quigley C (2002) Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 1: CD003447","journal-title":"Cochrane Database Syst Rev"},{"key":"657_CR11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0885-3924(02)00383-4","volume":"23","author":"Caldwell","year":"2002","unstructured":"Caldwell JR, Rapoport RJ, Davis JC et al. (2002) Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 23: 278\u2013291","journal-title":"J Pain Symptom Manage"},{"key":"657_CR12","first-page":"451","volume":"71","author":"Coluzzi","year":"2005","unstructured":"Coluzzi F, Mattia C (2005) Oxycodone. Pharmacological profile and clincial data in chronis pain management. Minerva Anestesiol 71: 451\u2013460","journal-title":"Minerva Anestesiol"},{"key":"657_CR13","first-page":"5","volume":"34","author":"Arzneimittelkommission","year":"2007","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft (2007) Empfehlungen zur Therapie von Tumorschmerzen. Arzneiverord Praxis 34: 5\u201319","journal-title":"Arzneiverord Praxis"},{"key":"657_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0304-3959(97)00072-9","volume":"73","author":"Heiskanen","year":"1997","unstructured":"Heiskanen T, Kalso E (1997) Controlled-release oxycodone and morphine in cancer related pain. Pain 73: 37\u201345","journal-title":"Pain"},{"key":"657_CR15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/026921639801200612","volume":"12","author":"Mercadante","year":"1998","unstructured":"Mercadante S (1998) Oxycodone in a patient reporting toxicities with multiple trials of opioids. Palliat Med 12: 466\u2013467","journal-title":"Palliat Med"},{"key":"657_CR16","first-page":"116","volume":"44","author":"Voorhorst","year":"1980","unstructured":"Voorhorst R, Sparreboom S (1980) Four cases of recurrent pseudo-scarlet fever caused by phenanthrene alkaloids with a 6-hydroxy group (codeine and morphine). Ann Allergy 44: 116\u2013120","journal-title":"Ann Allergy"},{"key":"657_CR17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1533-2500.2005.05106.x","volume":"5","author":"Fukshansky","year":"2005","unstructured":"Fukshansky M, Are M, Burton AW (2005) The role of opioids in cancer pain management. Pain Pract 5: 43\u201354","journal-title":"Pain Pract"},{"key":"657_CR18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/BF02244928","volume":"112","author":"De","year":"1993","unstructured":"De Wit H, Dudish S, Ambre J (1993) Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology 112: 324\u2013330","journal-title":"Psychopharmacology"},{"key":"657_CR19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1037\/1064-1297.6.4.367","volume":"6","author":"Kollins","year":"1998","unstructured":"Kollins SH, Rush CR, Pazzaglia PJ, Ali JA (1998) Comparison of acute behavioral effects of sustained-release and immediate-release. Exp Clin Psychopharmacol 6: 367\u2013374","journal-title":"Exp Clin Psychopharmacol"},{"key":"657_CR20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0885-3924(00)00195-0","volume":"20","author":"Fishman","year":"2000","unstructured":"Fishman SM, Wilsey B, Yang J et al. (2000) Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain Symptom Manage 20: 293\u2013307","journal-title":"J Pain Symptom Manage"},{"key":"657_CR21","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0022-3565(24)29229-6","volume":"299","author":"Marsch","year":"2001","unstructured":"Marsch LA, Bickel WK, Badger GJ et al. (2001) Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 299: 1056\u20131065","journal-title":"J Pharmacol Exp Ther"},{"key":"657_CR22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0376-8716(01)00127-2","volume":"64","author":"Roset","year":"2001","unstructured":"Roset PN, Farr\u00e9 M, de la Torre R et al. (2001) Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. Drug Alcohol Depend 64: 285\u2013298","journal-title":"Drug Alcohol Depend"},{"key":"657_CR23","unstructured":"Willweber-Strumpf A (2001) Missbrauch, Abh\u00e4ngigkeit. In: Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie. Wissensch. Verlags-Gesellschaft, Stuttgart, S\u00a0875\u2013888"},{"key":"657_CR24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00482-006-0491-6","volume":"20","author":"Hampel","year":"2006","unstructured":"Hampel C, Schenk M, G\u00f6bel H et al. (2006) Schmerztherapie bei suchtmittelabh\u00e4ngigen Patienten. Schmerz 20: 445\u2013459","journal-title":"Schmerz"},{"key":"657_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pain.2007.03.028","volume":"129","author":"Ballantyne","year":"2007","unstructured":"Ballantyne JC, LaForge KS (2007) Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129: 235\u2013255","journal-title":"Pain"},{"key":"657_CR26","unstructured":"Jage J, Jurna I (2001) Opioidanalgetika. In: Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie. Wissensch. Verlags-Gesellschaft, Stuttgart, S\u00a0255\u2013280"},{"key":"657_CR27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2003-41384","volume":"4","author":"Beck","year":"2003","unstructured":"Beck D (2003) Neue Entwicklungen in der Tumorschmerztherapie. Z Palliativmed 4: 43\u201348","journal-title":"Z Palliativmed"},{"key":"657_CR28","unstructured":"Diener HC, Kindler D, Maier C (2003) Medikament\u00f6se Schmerztherapie. In: Diener HC, Maier C (Hrsg) Das Schmerztherapie Buch. Urban & Fischer, M\u00fcnchen Jena, S\u00a0285\u2013342"},{"key":"657_CR29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0304-3959(02)00328-7","volume":"101","author":"Klepstad","year":"2003","unstructured":"Klepstad P, Kaasa S, Jystad \u00c5 et al. (2003) Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. Pain 101: 193\u2013198","journal-title":"Pain"},{"key":"657_CR30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s11916-000-0086-3","volume":"4","author":"Reddy","year":"2000","unstructured":"Reddy SK, Nguyen P (2000) Breakthrough pain in cancer patients: new therapeutic approaches to an old challenge. Curr Rev Pain 4: 242\u2013247","journal-title":"Curr Rev Pain"},{"key":"657_CR31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejpain.2004.06.001","volume":"9","author":"Svendsen","year":"2005","unstructured":"Svendsen KB, Andersen S, Arnason S et al. (2005) Breakthrough pain in malignant and non-malignant diseases: a rerview of prevalence, characteristics and mechanisms. Eur J Pain 9: 195\u2013206","journal-title":"Eur J Pain"},{"key":"657_CR32","first-page":"4","volume":"23","author":"Junker","year":"2007","unstructured":"Junker U, Ludwig H (2007) Opioide \u2013 differenzierte Therapie ist Goldstandard. Schmerztherapie 23: 4\u20138","journal-title":"Schmerztherapie"},{"key":"657_CR33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-2007-969041","volume":"1","author":"Pogatzki-Zahn","year":"2007","unstructured":"Pogatzki-Zahn EM, Zahn PK (2007) Postoperative Akutschmerztherapie \u2013 Neue M\u00f6glichkeiten der systematischen Analgesie. Anasthesiol Intensivmed Notfallmed Schmerzther 1: 22\u201331","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"key":"657_CR34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.tips.2004.12.007","volume":"26","author":"Samaha","year":"2005","unstructured":"Samaha A-N, Robinson TE (2005) Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 26: 82\u201387","journal-title":"Trends Pharmacol Sci"},{"key":"657_CR35","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23: 1296\u20131310","journal-title":"Clin Ther"},{"key":"657_CR36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s005200100274","volume":"10","author":"Donnelly","year":"2002","unstructured":"Donnelly S, Davis MP, Walsh D, Naughton M (2002) Morphine in cancer pain management: a practical guide. Support Care Cancer 10: 13\u201335","journal-title":"Support Care Cancer"},{"key":"657_CR37","first-page":"A2720","volume":"103","author":"Baron","year":"2006","unstructured":"Baron R (2006) Diagnostik und Therapie neuropathischer Schmerzen. Dtsch \u00c4rztebl 103: A2720\u2013A2730","journal-title":"Dtsch \u00c4rztebl"},{"key":"657_CR38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00482-003-0257-3","volume":"17","author":"Azad","year":"2003","unstructured":"Azad SC, Zieglg\u00e4nsberger W (2003) Was wissen wir \u00fcber die Chronifizierung von Schmerz? Schmerz 17: 441\u2013444","journal-title":"Schmerz"},{"key":"657_CR39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0169-328X(99)00021-2","volume":"66","author":"Wang","year":"1999","unstructured":"Wang Z, Zhou Y, Spangler R et al. (1999) Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in rat brain. Mol Brain Res 66: 184\u2013187","journal-title":"Mol Brain Res"},{"key":"657_CR40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1749-6632.2001.tb03557.x","volume":"937","author":"Kreek","year":"2001","unstructured":"Kreek MJ (2001) Drug addictions: molecular and cellular endpoints. Ann N Y Acad Sci 937: 27\u201349","journal-title":"Ann N Y Acad Sci"},{"key":"657_CR41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bpa.2006.12.001","volume":"21","author":"Kehlet","year":"2006","unstructured":"Kehlet H, Wilkinson RC, Fischer HB, Camu F, Prospect Working Group (2006) PROSPECT: evidence-based, procedure-specific postoperative pain management. Best Pract Res Clin Anaesthesiol 21: 149\u2013159","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"657_CR42","unstructured":"Gehling M, Tryba M (2001) Unterschiede zwischen akutem und chronischem Schmerz. In: Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie. Wissensch. Verlags-Gesellschaft, Stuttgart, S\u00a0565\u2013575"},{"key":"657_CR43","unstructured":"M\u00fcller-Schwefe G (1998) Der Frankfurter Konsensus. Der Deutsche Schmerztag 1998, Frankfurt. http:\/\/www.schmerz-therapie-deutschland.de\/pages\/DGS\/DGS_11.html."},{"key":"657_CR44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1055\/s-2003-39360","volume":"38","author":"Ohnesorge","year":"2003","unstructured":"Ohnesorge H, Siebrecht D, Gleim M (2003) Tumorschmerztherapie. Anasthesiol Intensivmed Notfallmed Schmerzther 38: 403\u2013437","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"key":"657_CR45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-2003-36558","volume":"38","author":"Freye","year":"2003","unstructured":"Freye E, Latasch L (2003) Entwicklung der Opioidtoleranz \u2013 molekularer Mechanismus und klinische Konsequenzen. Anasthesiol Intensivmed Notfallmed Schmerzther 38: 14\u201326","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"key":"657_CR46","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1345\/aph.1G259","volume":"40","author":"Amabile","year":"2006","unstructured":"Amabile CM, Bowman BJ (2006) Overview of oral modified-release opioid products for the management of chronic pain. Ann Pharmacother 40: 1327\u20131335","journal-title":"Ann Pharmacother"},{"key":"657_CR47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(97)00012-2","volume":"14","author":"Broomhead","year":"1997","unstructured":"Broomhead A, Kerr R, Tester W et al. (1997) Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 14: 63\u201373","journal-title":"J Pain Symptom Manage"},{"key":"657_CR48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s002280050675","volume":"55","author":"Peat","year":"1999","unstructured":"Peat S, Sweet P, Miah Y et al. (1999) Assessment of analgesia in human chronic pain. Randomized double-blind crossover study of once daily repro-dose morphine versus MST continus. Eur J Clin Pharmacol 55: 577\u2013581","journal-title":"Eur J Clin Pharmacol"},{"key":"657_CR49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0304-3959(96)03269-1","volume":"69","author":"Gourlay","year":"1997","unstructured":"Gourlay GK, Cherry DA, Onley MM et al. (1997) Pharmacokinetics and pharmacodynamics of twenty-four-hourly kapanol compared to twelve-hourly MS contin in the treatment of severe cancer pain. Pain 69: 295\u2013302","journal-title":"Pain"},{"key":"657_CR50","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0885-3924(02)00382-2","volume":"23","author":"Portenoy","year":"2002","unstructured":"Portenoy RK, Sciberras A, Eliot L et al. (2002) Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation avinza\u00ae, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage 23: 292\u2013300","journal-title":"J Pain Symptom Manage"},{"key":"657_CR51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jpainsymman.2004.04.015","volume":"29","author":"Hagen","year":"2005","unstructured":"Hagen NA, Thirlwell M, Eisenhoffer J et al. (2005) Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS contin XL\u00ae) in cancer pain. J Pain Symptom Manage 29: 80\u201390","journal-title":"J Pain Symptom Manage"},{"key":"657_CR52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5055\/jom.2006.0025","volume":"2","author":"Rauck","year":"2006","unstructured":"Rauck RL, Bookbinder SA, Bunker TR et al. (2006) The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag 2: 155\u2013166","journal-title":"J Opioid Manag"},{"key":"657_CR53","doi-asserted-by":"crossref","unstructured":"Wallace MS, Thipphawong J (2007) Clinical trial results with OROS hydromorphone. J Pain Symtpom Manage 33 [suppl 2]: S25\u2013S32","DOI":"10.1016\/j.jpainsymman.2006.09.008"},{"key":"657_CR54","unstructured":"Giesecke T, Schein J, Kosinski M, Bornh\u00f6vd K (2006) Schlafqualit\u00e4t von Patienten mit Arthrose des H\u00fcft- oder Kniegelenks: Ergebnisse eines randomisierten, kontrollierten Vergleichs von Jurnista\u00ae (OROS\u00ae-Hydromorphon 1\u00d7 t\u00e4glich) mit retardiertem Oxycodon. Schmerz 20 [suppl 1]: 88"},{"key":"657_CR55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pain.2005.10.007","volume":"120","author":"Odrcich","year":"2006","unstructured":"Odrcich M, Bailey JM, Cahill CM, Gilron I (2006) Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain 120: 207\u2013212","journal-title":"Pain"},{"key":"657_CR56","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pain.2004.03.039","volume":"110","author":"Perissin","year":"2004","unstructured":"Perissin L, Boccalon S, Scaggiante B et al. (2004) Diurnal changes of tonic nociceptive responses in mice: evidence for a proalgesic role of melatonin. Pain 110: 250\u2013258","journal-title":"Pain"},{"key":"657_CR57","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0304-3959(94)00204-R","volume":"61","author":"Gourlay","year":"1995","unstructured":"Gourlay GK, Plummer JL, Cherry DA (1995) Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution. Pain 61: 375\u2013381","journal-title":"Pain"},{"key":"657_CR58","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jpainsymman.2004.10.008","volume":"29","author":"Grosset","year":"2005","unstructured":"Grosset AB, Roberts MS, Woodson ME et al. (2005) Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled tria. J Pain Symptom Manage 29: 584\u2013594","journal-title":"J Pain Symptom Manage"},{"key":"657_CR59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpainsymman.2006.10.011","volume":"34","author":"Currow","year":"2007","unstructured":"Currow DC, Plummer JL, Cooney NJ et al. (2007) A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer. J Pain Symptom Manage 34: 17\u201323","journal-title":"J Pain Symptom Manage"},{"key":"657_CR60","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jpainsymman.2004.02.024","volume":"28","author":"Mercadante","year":"2004","unstructured":"Mercadante S, Villari P, Ferrera P, Casuccio A (2004) Optimization of opioid therapy f\u00fcr preventing incident pain associated with bone metastases. J Pain Symptom Manage 28: 505\u2013510","journal-title":"J Pain Symptom Manage"},{"key":"657_CR61","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000022097","volume":"45","author":"M\u00fchlberg","year":"1999","unstructured":"M\u00fchlberg W, Platt D (1999) Age-dependent changes of the kidneys: Pharmacological implications. Gerontology 45: 243\u2013253","journal-title":"Gerontology"},{"key":"657_CR62","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1055\/s-2007-979384","volume":"132","author":"Saile","year":"2007","unstructured":"Saile P, Fiedler R, Markau S et al. (2007) Bestimmung der Nierenfunktion im klinischen Alltag \u2013 welche Methode ist die beste? Dtsch Med Wochenschr 132: 1093\u20131097","journal-title":"Dtsch Med Wochenschr"},{"key":"657_CR63","unstructured":"Thummel KE, Shen DD, Isoherranen N, Smith HE (2006) Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman\u2019s the pharmacological basis of therapeutics. McGraw-Hill, New York, pp\u00a01787\u20131888"},{"key":"657_CR64","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0024-3205(95)00010-4","volume":"56","author":"Mignat","year":"1995","unstructured":"Mignat C, Wille U, Ziegler A (1995) Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci 56: 793\u2013799","journal-title":"Life Sci"},{"key":"657_CR65","doi-asserted-by":"crossref","unstructured":"L\u00f6tsch J (2005) Opioid metabolites. J Pain Symptom Manage 29 [suppl 5]: S10\u2013S24","DOI":"10.1016\/j.jpainsymman.2005.01.004"},{"key":"657_CR66","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.292.6535.1548","volume":"J","author":"Osborne","year":"1986","unstructured":"Osborne RJ, Joel SP, Slevin ML (1986) Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) 292: 1548\u20131549","journal-title":"Br Med"},{"key":"657_CR67","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2125.1989.tb05401.x","volume":"27","author":"Hasselstrom","year":"1989","unstructured":"Hasselstrom J, Berg U, Lofgren A, Sawe J (1989) Long lasting respiratory depression induced by morphine-6-glucuronide? Br J Clin Pharmacol 27: 515\u2013518","journal-title":"Br J Clin Pharmacol"},{"key":"657_CR68","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/096032719000900509","volume":"9","author":"Bodd","year":"1990","unstructured":"Bodd E, Jacobsen D, Lund E et al. (1990) Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum Exp Toxicol 9: 317\u2013321","journal-title":"Hum Exp Toxicol"},{"key":"657_CR69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0885-3924(91)90961-3","volume":"6","author":"Hagen","year":"1991","unstructured":"Hagen NA, Foley KM, Cerbone DJ et al. (1991) Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 6: 125\u2013128","journal-title":"J Pain Symptom Manage"},{"key":"657_CR70","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1055\/s-2007-1024449","volume":"124","author":"Dubs","year":"1999","unstructured":"Dubs A, Wiedemeier P, Caduff B (1999) Morphinvergiftung bei chronischer Niereninsuffizienz. Morphine-6-glucuronid als pharmakologisch aktiver Morphin-Metabolit. Dtsch Med Wochenschr 124: 896\u2013898","journal-title":"Dtsch Med Wochenschr"},{"key":"657_CR71","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/00000542-200005000-00038","volume":"92","author":"Angst","year":"2000","unstructured":"Angst MS, Buhrer M, Lotsch J (2000) Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology 92: 1473\u20131476","journal-title":"Anesthesiology"},{"key":"657_CR72","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/00498250110119090","volume":"32","author":"Zheng","year":"2002","unstructured":"Zheng M, McErlane KM, Ong MC (2002) Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient. Xenobiotica 32: 427\u2013439","journal-title":"Xenobiotica"},{"key":"657_CR73","first-page":"701","volume":"55","author":"Fitzgerald","year":"1991","unstructured":"Fitzgerald J (1991) Narcotic analgesics in renal failure. Conn Med 55: 701\u2013704","journal-title":"Conn Med"},{"key":"657_CR74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00520-004-0730-2","volume":"13","author":"Hanks","year":"2005","unstructured":"Hanks GW, Reid C (2005) Contribution to variability in response to opioids. Support Care Cancer 13: 145\u2013152","journal-title":"Support Care Cancer"},{"key":"657_CR75","doi-asserted-by":"crossref","unstructured":"Freye E (2004) Opioide in der Medizin, 6. Aufl. Springer, Berlin Heidelberg New York, S\u00a0137\u2013139","DOI":"10.1007\/978-3-662-09096-1"},{"key":"657_CR76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0952-8180(95)00092-5","volume":"8","author":"Kirvela","year":"1996","unstructured":"Kirvela M, Lindgren L, Seppala T, Olkkola KT (1996) The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8: 13\u201318","journal-title":"J Clin Anesth"},{"key":"657_CR77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.smj.0000242876.45747.0a","volume":"100","author":"Foral","year":"2007","unstructured":"Foral PA, Ineck JR, Nystrom KK (2007) Oxycodone accumulation in a hemodialysis patient. South Med J 100: 212\u2013214","journal-title":"South Med J"},{"key":"657_CR78","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/clpt.1993.43","volume":"53","author":"Otton","year":"1993","unstructured":"Otton SV, Wu D, Joffe RT et al. (1993) Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 53: 401\u2013409","journal-title":"Clin Pharmacol Ther"},{"key":"657_CR79","first-page":"A1256","volume":"104","author":"Anonymus","year":"2007","unstructured":"Anonymus (2007) Stufenplanverfahren f\u00fcr Oxycodon-Generika angeordnet \u2013 Interaktionen bei Alkoholkonsum. Dtsch \u00c4rztebl 104: A1256","journal-title":"Dtsch \u00c4rztebl"},{"key":"657_CR80","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/01.jcp.0000085421.74359.60","volume":"23","author":"De","year":"2003","unstructured":"De Leon J, Dinsmore L, Wedlund P (2003) Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 23: 420\u2013421","journal-title":"J Clin Psychopharmacol"},{"key":"657_CR81","first-page":"913","volume":"254","author":"Bryant","year":"1988","unstructured":"Bryant HU, Bernton EW, Holoday J (1988). Morphine pellet induced immunomodulation in mice: temporal relation-ships. J Pharmacol Exp Ther 254: 913\u2013920","journal-title":"J Pharmacol Exp Ther"},{"key":"657_CR82","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/sj.bjp.0701138","volume":"121","author":"Sacerdote","year":"1997","unstructured":"Sacerdote P, Manfredi B, Mantegazza P, Panerai AE (1997) Antinociceptive and immuno-suppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 121: 834\u2013840","journal-title":"Br J Pharmacol"},{"key":"657_CR83","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/00000539-200006000-00028","volume":"90","author":"Sacerdote","year":"2000","unstructured":"Sacerdote P, Bianchi M, Gaspani L et al. (2000) The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 90: 1411\u20131414","journal-title":"Anesth Analg"},{"key":"657_CR84","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.V95.6.2031","volume":"95","author":"Sacerdote","year":"2000","unstructured":"Sacerdote P, Manfredi B, Gaspani L, Panerai AE (2000) The opioid antagonist naloxone in-duces a shift from type 2 to type 1 cytokine pattern in BALB\/cJ mice. Blood 95: 2031\u20132036","journal-title":"Blood"},{"key":"657_CR85","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/archsurg.1991.01410280056007","volume":"126","author":"Yeager","year":"1991","unstructured":"Yeager MP, Colacchio TA (1991) Effect of morphine on growth of metastatic colon cancer in vivo. Arch Surg 126: 454\u2013456","journal-title":"Arch Surg"},{"key":"657_CR86","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00000542-199509000-00008","volume":"83","author":"Yeager","year":"1995","unstructured":"Yeager MP, Colacchio TA, Yu CT et al. (1995) Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 83: 500\u2013508","journal-title":"Anesthesiology"},{"key":"657_CR87","doi-asserted-by":"crossref","unstructured":"Sacerdote P (2006) Opioids and the immune system. Palliat Med 20 [suppl 1]: s9\u2013s15","DOI":"10.1191\/0269216306pm1124oa"},{"key":"657_CR88","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.biopha.2006.06.015","volume":"60","author":"Budd","year":"2006","unstructured":"Budd K (2006) Pain management: is opioid immunosuppression a clincal problem? Biomed Pharmacother 60: 310\u2013317","journal-title":"Biomed Pharmacother"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-008-0657-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00482-008-0657-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-008-0657-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T09:14:32Z","timestamp":1738228472000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00482-008-0657-5"}},"subtitle":["Applikationsintervalle, Metabolismus und Immunsuppression","Application intervals, metabolism and immunosuppression"],"short-title":[],"issued":{"date-parts":[[2008,5,17]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1007\/s00482-008-0657-5","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"type":"print","value":"0932-433X"},{"type":"electronic","value":"1432-2129"}],"subject":[],"published":{"date-parts":[[2008,5,17]]}}}